TecDAX

EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023

Retrieved on: 
Saturday, May 13, 2023
Partnership, Evotec, Capital market, TecDAX, CDAX, Bristol Myers Squibb, Research, Novartis, EBITDA, Annual report, ISIN, Frankfurt Stock Exchange, ESG, EVO, MDAX, Cryptocurrency, Pharmaceutical industry

PUBLICATION OF ANNUAL REPORT 2022: “AHEAD OF THE CURVE”

Key Points: 
  • PUBLICATION OF ANNUAL REPORT 2022: “AHEAD OF THE CURVE”
    Evotec SE (Frankfurt Stock Exchange: Prime Standard, ISIN: DE0005664809; NASDAQ: EVO) today published its Annual Report for the fiscal year 2022, as well as the qualitative Quarterly Statement for the first quarter of 2023.
  • Evotec’s fully audited Annual Report 2022 “Ahead of the Curve” is now available for downloading on www.evotec.com/financial-reports .
  • Evotec had published preliminary financial results for FY2022 already on 28 March, which have remained unchanged.
  • Evotec also published a qualitative Quarterly Statement for the first quarter of 2023 today.

EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023

Retrieved on: 
Thursday, May 11, 2023
Medicine, Radiation, Radionuclide, TecDAX, HDR, Sale, EUR, Federal Executive Boards, ISIN, Growth, Lithium

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023.

Key Points: 
  • Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023.
  • The significant increase in sales results from the sustainable growth in demand for radioisotopes for pharmaceutical and industrial applications.
  • The main growth driver continues to be the pharmaceutical radioisotope business, and sales of laboratory equipment also increased again.
  • The Executive Board continues to expect sales of just under EUR 230 million and net income of around EUR 25 million.

EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

Retrieved on: 
Tuesday, May 9, 2023
Blood pressure, Primary aldosteronism, CT, CXCR4, Heart failure, Gland, Hypertension, Stroke, APA, TecDAX, BAH, Nuclear medicine, File association, Trial of the century, Investigator, Aldosterone, Patient, Risk, Hyperplasia, Adenoma, Chief medical informatics officer, Surgeon, Hudson Institute, ISIN, Principal, Monash, AVS, Eckert, Pharmaceutical industry, Medical imaging, Gallium

Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.

Key Points: 
  • Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.
  • It would most likely have a large impact on clinical practice and enable a large number of hypertension patients to be cured.
  • The study in Australia is in line with clinical activities in Europe and in the USA, which are supported by PentixaPharm.
  • [68Ga]Ga-PentixaFor is being developed by Eckert & Ziegler's subsidiary PentixaPharm GmbH also as a superiorly sensitive diagnostic for a portfolio of hematooncological malignancies.

EQS-News: Siltronic AG: Dr. Michael Heckmeier takes over as CEO of Siltronic AG - Annual General Meeting approves dividend of EUR 3 per share

Retrieved on: 
Friday, May 5, 2023
Speech, Annual, Supervisory board, TecDAX, Computer, Silicon, EUR, Mariella, National Executive Board of the Boy Scouts of America, Artificial intelligence, Environment, News, MDAX, Annual general meeting, Management, Holding company, Security (finance), Cryptocurrency, Siltronic

After three years in virtual format, Siltronic AG's Annual General Meeting took place in person.

Key Points: 
  • After three years in virtual format, Siltronic AG's Annual General Meeting took place in person.
  • The shareholders followed the proposal of the Executive Board and Supervisory Board to distribute a dividend of EUR 3.00 per share.
  • A total of 69.03 percent of Siltronic AG's share capital was represented at the Annual General Meeting.
  • His successor, Michael Heckmeier, attended the Annual General Meeting as a guest and introduced himself to the shareholders in a short speech.

EQS-News: NFON AG: Patrik Heider becomes new Chairman of the Board of NFON AG

Retrieved on: 
Monday, April 24, 2023
Financial Oversight and Management Board for Puerto Rico, Communication, CFOO, Supervisory board, Bavaria, TecDAX, Heider, Spokesperson, Nemetschek, Federal Executive Boards, CFO, Growth, MDAX, Konstanz University of Applied Sciences, Management

Munich, 24 April 2023 - The Supervisory Board of NFON AG has unanimously appointed Mr Patrik Heider as Chief Executive Officer of NFON AG with effect from 15 May 2023.

Key Points: 
  • Munich, 24 April 2023 - The Supervisory Board of NFON AG has unanimously appointed Mr Patrik Heider as Chief Executive Officer of NFON AG with effect from 15 May 2023.
  • In this role, Patrik Heider will define the further strategic direction of NFON and lead the company into the next phase of growth and innovation.
  • "With Patrik Heider, we have been able to gain a highly experienced and international manager with exceptional leadership qualities as CEO.
  • Added to this is his excellent capital market experience, which is essential for the further development of NFON," says Rainer Koppitz, Chairman of the Supervisory Board of NFON AG.

EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

Retrieved on: 
Thursday, April 20, 2023
GMP, Medicine, Glomus tumor, TecDAX, PET, Radiopharmaceutical, Federal Executive Boards, ISIN, DMF, Eckert, Prostate cancer, Medical imaging, Lutetium

Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added Lu-177) in GMP grade from the competent German authority.

Key Points: 
  • Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added Lu-177) in GMP grade from the competent German authority.
  • The approval is the basis for the marketing authorization of Lutetium-177 as a drug, but also for use of this radioisotope as a starting material for the manufacture of radiopharmaceuticals.
  • By making Lutetium available to a significantly broader range of users, the approval will enable Eckert & Ziegler to further continue its successful strategy as one of the world leading isotope suppliers.
  • The beta emitting Lutetium-177 is linked to a tumor specific ligand which then targets the tumor cells to destroy them.

EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

Retrieved on: 
Saturday, April 15, 2023
GMP, Medicine, Radionuclide, PSMA, Actinium-225, TecDAX, Research, Radiopharmaceutical, ISIN, Medical imaging

Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).

Key Points: 
  • Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).
  • Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands.
  • Eckert & Ziegler is currently developing a production process to be capable of supplying significant amounts of the highly demanded radionuclide Ac-225 to the market.
  • “This agreement with Eckert & Ziegler contributes to our continued research and development with Actinium-225, an exciting therapeutic isotope.

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

Retrieved on: 
Tuesday, April 4, 2023
GMP, Medicine, Radionuclide, PSMA, Actinium-225, TecDAX, Research, Radiopharmaceutical, ISIN, Medical imaging

BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).

Key Points: 
  • BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).
  • Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands.
  • Eckert & Ziegler is currently developing a production process to be capable of supplying significant amounts of the highly demanded radionuclide Ac-225 to the market.
  • “This agreement with Eckert & Ziegler contributes to our continued research and development with Actinium-225, an exciting therapeutic isotope.

EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle

Retrieved on: 
Friday, March 31, 2023
Wacker Chemie, IPO, International, Electronics, Head, Supervisory board, TecDAX, Kearney (consulting firm), Computer, Wind, Treasury, Silicon, Frankfurt Stock Exchange, Group Control System, Corporation, CFO, Growth, News, MDAX, Management, Saarland University, Siltronic

Munich, March 30, 2023 – Claudia Schmitt will become the new CFO of Siltronic AG effective July 1, 2023.

Key Points: 
  • Munich, March 30, 2023 – Claudia Schmitt will become the new CFO of Siltronic AG effective July 1, 2023.
  • She succeeds Rainer Irle (53), who has been CFO of Siltronic AG since 2013 and will leave the company at his own request.
  • "We are very pleased to introduce Claudia Schmitt as an experienced successor to Rainer Irle from Siltronic's own ranks," said Dr. Tobias Ohler, Chairman of the Supervisory Board of Siltronic AG.
  • "With Claudia Schmitt, an excellent choice was made as successor to my Executive Board colleague Rainer Irle.

EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022

Retrieved on: 
Friday, March 31, 2023
Medicine, Bank statement, Annual, Isotope, TecDAX, Radiopharmaceutical, USD, Federal Executive Boards, Acquisition, Supervisory board, ISIN, Growth

Berlin, 30 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022.

Key Points: 
  • Berlin, 30 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022.
  • Net income reached € 29.3 million, thus increasing by nearly 20% compared to the previous year's figure adjusted for special effects.
  • The reason for the increase is the acquisition of the Argentinian Tecnonuclear S.A. in 2022 and a strong Asian business.
  • Cash and cash equivalents as of 31 December 2022 decreased to € 82.7 million; less loan liabilities, net liquidity amounted to € 60.3 million.